Literature DB >> 23352267

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.

Leslie W Tari1, Michael Trzoss, Daniel C Bensen, Xiaoming Li, Zhiyong Chen, Thanh Lam, Junhu Zhang, Christopher J Creighton, Mark L Cunningham, Bryan Kwan, Mark Stidham, Karen J Shaw, Felice C Lightstone, Sergio E Wong, Toan B Nguyen, Jay Nix, John Finn.   

Abstract

The bacterial topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE) are essential enzymes that control the topological state of DNA during replication. The high degree of conservation in the ATP-binding pockets of these enzymes make them appealing targets for broad-spectrum inhibitor development. A pyrrolopyrimidine scaffold was identified from a pharmacophore-based fragment screen with optimization potential. Structural characterization of inhibitor complexes conducted using selected GyrB/ParE orthologs aided in the identification of important steric, dynamic and compositional differences in the ATP-binding pockets of the targets, enabling the design of highly potent pyrrolopyrimidine inhibitors with broad enzymatic spectrum and dual targeting activity.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23352267     DOI: 10.1016/j.bmcl.2012.11.032

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

1.  In vitro activity of novel gyrase inhibitors against a highly resistant population of Pseudomonas aeruginosa.

Authors:  Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

2.  Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase.

Authors:  Rupesh Kumar; Bhavani Shankar Madhumathi; Valakunja Nagaraja
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

3.  Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase.

Authors:  Logan D Andrews; Timothy R Kane; Paola Dozzo; Cat M Haglund; Darin J Hilderbrandt; Martin S Linsell; Timothy Machajewski; Glen McEnroe; Alisa W Serio; Kenneth B Wlasichuk; David B Neau; Svetlana Pakhomova; Grover L Waldrop; Marc Sharp; Joe Pogliano; Ryan T Cirz; Frederick Cohen
Journal:  J Med Chem       Date:  2019-08-09       Impact factor: 7.446

4.  Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Authors:  Neil R Stokes; Helena B Thomaides-Brears; Stephanie Barker; James M Bennett; Joanne Berry; Ian Collins; Lloyd G Czaplewski; Vicki Gamble; Paul Lancett; Alastair Logan; Christopher J Lunniss; Hilary Peasley; Stéphanie Pommier; Daniel Price; Carol Smee; David J Haydon
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

5.  Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design.

Authors:  Jason B Cross; Jing Zhang; Qingyi Yang; Michael F Mesleh; Jan Antoinette C Romero; Bin Wang; Doug Bevan; Katherine M Poutsiaka; Felix Epie; Terence Moy; Anu Daniel; Joseph Shotwell; Brian Chamberlain; Nicole Carter; Ole Andersen; John Barker; M Dominic Ryan; Chester A Metcalf; Jared Silverman; Kien Nguyen; Blaise Lippa; Roland E Dolle
Journal:  ACS Med Chem Lett       Date:  2016-02-16       Impact factor: 4.345

6.  Anticancer Properties of Halogenated Pyrrolo[3,2-d]pyrimidines with Decreased Toxicity via N5 Substitution.

Authors:  Brian M Cawrse; Rena S Lapidus; Brandon Cooper; Eun Yong Choi; Katherine L Seley-Radtke
Journal:  ChemMedChem       Date:  2017-12-18       Impact factor: 3.466

7.  Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

Authors:  Leslie W Tari; Xiaoming Li; Michael Trzoss; Daniel C Bensen; Zhiyong Chen; Thanh Lam; Junhu Zhang; Suk Joong Lee; Grayson Hough; Doug Phillipson; Suzanne Akers-Rodriguez; Mark L Cunningham; Bryan P Kwan; Kirk J Nelson; Amanda Castellano; Jeff B Locke; Vickie Brown-Driver; Timothy M Murphy; Voon S Ong; Chris M Pillar; Dean L Shinabarger; Jay Nix; Felice C Lightstone; Sergio E Wong; Toan B Nguyen; Karen J Shaw; John Finn
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 8.  Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.

Authors:  Michael A Reiche; Digby F Warner; Valerie Mizrahi
Journal:  Front Mol Biosci       Date:  2017-11-14

9.  Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1.

Authors:  Abedawn I Khalaf; Judith K Huggan; Colin J Suckling; Colin L Gibson; Kirsten Stewart; Federica Giordani; Michael P Barrett; Pui Ee Wong; Keri L Barrack; William N Hunter
Journal:  J Med Chem       Date:  2014-07-29       Impact factor: 7.446

10.  Discovery of Two Brominated Oxindole Alkaloids as Staphylococcal DNA Gyrase and Pyruvate Kinase Inhibitors via Inverse Virtual Screening.

Authors:  Ahmed M Sayed; Hani A Alhadrami; Seham S El-Hawary; Rabab Mohammed; Hossam M Hassan; Mostafa E Rateb; Usama Ramadan Abdelmohsen; Walid Bakeer
Journal:  Microorganisms       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.